This week in drug discovery (8-12 August)  

News round-up by DDW’s Reece Armstrong for 8-12 August 

New insights into melanoma, a company transition into life sciences and a Lyme disease vaccine are some of the stories in this week’s news round-up.

Pfizer launches Phase III trial for Lyme disease vaccine   

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva.   

Cerevance teams up with Merck (MSD) on Alzheimer’s project   

Drug discovery and development company Cerevance has announced a multi-year strategic research collaboration with Merck (MSD), focused on identifying novel targets for Alzheimer’s disease.   

Oxeia Biopharmaceuticals encouraged by concussion treatment  

Clinical stage biotech company Oxeia Biopharmaceuticals has announced interim results from a Phase II trial investigating its treatment for concussion.  

PerkinElmer focuses on life sciences in $2.45bn deal 

Life sciences company PerkinElmer will divest its Applied, Food and Enterprise Services to the private equity firm New Mountain Capital in a potential deal worth $2.45 billion. 

Scientists discover how melanoma invades new tissue   

Scientists have discovered how melanoma skin cancer cells invade new tissues in research they hope might lead to new treatments.  

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free